In Focus
Geltec Healthcare diversifies its business in a dynamic market SINCE THE COMPANY’S LAUNCH IN 2019 IN THE UAE AND AFTER BEING RECENTLY ACQUIRED BY ‘GLOBALONE HEALTHCARE HOLDINGS LLC’ THE HEALTHCARE DIVISION OF YAS HOLDING, ITS MISSION HAS BEEN TO DELIVER SCIENCE-LED INNOVATIONS AND HEALTHCARE SOLUTIONS THAT SIGNIFICANTLY IMPROVE PATIENTS’ LIVES IN THE UAE AND BEYOND Being aligned with Dubai’s Industrial Strategy 2030 that was launched in 2016 by His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice-President and Prime Minister of the UAE and Ruler of Dubai, of which Healthcare is a key pillar, Geltec focuses on strengthening the UAE healthcare sector and further enhancing the provision of world-class pharmaceuticals to the US, European and, GCC markets. In the first quarter of 2019, the Geltec Group launched its new production plant, manufacturing dietary supplements and pharmaceutical formulations in soft gelatin capsules and gelatin enrobed tablet forms in the UAE. Under the leadership of ‘GlobalOne Healthcare Holdings LLC’ the healthcare arm of Yas Holdig, Geltec strategically works to create a market that is attractive for global pharmaceutical companies to manufacture and distribute their products in the UAE, aiming to achieve exponential
growth in the health sector. With a total production capacity of 1.5 Billion Soft gels / Tab Gels per annum, Geltec under the leadership of Yas Holding plans to invest in further expansion to include oral solid tablets. An environment-friendly facility Geltec’s state-of-the-art “Green Building Certified” facility in Jafza, designed to comply with USFDA standards, has strong environmental credentials. Audited and approved by NSF GMP for OTC Monograph products and with a UL Social compliance audit successfully completed in 2019, the site currently supplies OTC Monograph products to pharmaceutical industry leaders in the USA and globally. The facility is also approved as a supplier for the products of global pharmaceutical companies. The manufacturing facility is supported by an experienced regulatory team that handles the listing and registra-
Geltec’s state-of-the-art “Green Building Certified” facility in Jafza, designed to comply with USFDA standards, has strong environmental credentials.
tion in various markets including the US, EU and the Middle East. Embracing technology-enabled solutions Technology and innovation have been core pillars of Geltec. The manufacturing takes place in a classified area that contains fully automatic vessels with CleanIn-Place (CIP) systems. Capsules are produced using a Hi-Tech encapsulation machine from Canada that delivers hermetically sealed high-quality capsules. A laser-guided camera system in the inspection and printing machines ensures high-quality output. The unidirectional process flow is an added advantage to the manufacturing processes. Environmental conditions and differential pressure inside the plant is managed through automatically controlled HAVAC systems, with 99.9 per cent HEPA filters. Both the finished product and raw materials involved in the manufacturing process are tested and released in line with British and/or US pharmacopeial specifications using advanced analytical equipment meeting 21CFR regulations. Tackling the challenges of an unstable market Through the establishment of mutually rewarding business relationships with many leading multinational companies along with renowned global healthcare organisations, the emerging need of Geltec’s
20
Issue 61 | May - June 2021
